Panbela Q1 net loss $7.1M; ASPIRE trial interim analysis delayed to Q1 2025 due to lower event rate

Panbela Therapeutics, Inc.

ASPIRE trial interim OS analysis delayed to Q1 2025; lower-than-expected event rate may signal improved survival.
ASPIRE enrollment >50%; complete enrollment of ~600 patients expected by Q1 2025.
Q1 2024 R&D expenses $5.5M (up from $3.5M YoY) driven by ASPIRE expansion; net loss per share $2.28.
Cash $262k as of March 31; closed $9.0M public offering in January; $0.8M nondilutive payment from US WorldMeds in April.
Stock moved to OTCQB; new US and Canada patent for eflornithine/sulindac fixed dose combination.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Panbela Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income Net loss in the quarter was approximately $7.1 million, or $2.28 per diluted share, EPS $2.28 per diluted share.

Period: the quarter ended March 31, 2024
Net income: Net loss in the quarter was approximately $7.1 million, or $2.28 per diluted share
EPS: $2.28 per diluted share
Result: reported results

Exact text from the filing

Net loss in the quarter was approximately $7.1 million, or $2.28 per diluted share, compared to a net loss of $5.1 million, or $392.76 per diluted share, in the same period last year.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001437749-24-017059

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.